Is GALECTIN THERAPEUTICS INC (GALT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 53.2% / 30% | 7.6% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 53.2% / 33% | 7.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 607.3% / 33% | 86.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 53.2% / 33% | 7.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 607.3% / 33% | 86.4% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -87.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$42M |
| Free Cash Flow | -$42M |
| Total Debt | $106M |
| Current Ratio | 0.1 |
| Total Assets | $17M |
Price & Trading
| Last Close | $2.80 |
| 50-Day MA | $2.99 |
| 200-Day MA | $3.93 |
| Avg Volume | 356K |
| Beta | 1.0 |
|
52-Week Range
$1.12
| |
About GALECTIN THERAPEUTICS INC (GALT)
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is GALECTIN THERAPEUTICS INC (GALT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), GALECTIN THERAPEUTICS INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is GALECTIN THERAPEUTICS INC's debt ratio?
GALECTIN THERAPEUTICS INC's debt ratio is 53.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 607.3%.
What are GALECTIN THERAPEUTICS INC's key financial metrics?
GALECTIN THERAPEUTICS INC has a market capitalization of $173M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.